1-4 of 4
Michael P Osborn
Close
Sort by
Journal Articles

High Prevalence of Relapse in Australian Children with Ph-like Acute Lymphoblastic Leukemia Despite Risk Adapted Treatment

Susan L Heatley, PhD MD, Teresa Sadras, PhD, Eva Nievergall, PhD, Chung Hoow Kok, PhD, Phuong Dang, BSci (Hon), Kelly Quek, PhD, Nicola C Venn, Sarah Moore, BSc (Hon), FFSc (RCPA), Tamara Law, BSc (Hons), Anthea Ng, BAppSc, MSc, Murray D Norris, PhD, Tamas Revesz, MD PhD, Michael P Osborn, MBBS, Chris Fraser, FRACP, MBBS, MPH, Frank Alvaro, MBBS, FRACP, Glenn M Marshall, MBBS, MD FRACP, Luciano Dalla Pozza, MBBS, FRACP, Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Charles G. Mullighan, MBBS, MSc, MD, Rosemary Sutton, PhD, Deborah L White, PhD FFSc (RCPA)
Journal: Blood
Blood (2015) 126 (23): 1419.
https://doi.org/10.1182/blood.V126.23.1419.1419
Published: 2015
Journal Articles

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets

Clinical Trials & Observations
David T. Yeung, Michael P. Osborn, Deborah L. White, Susan Branford, Jodi Braley, Alan Herschtal, Michael Kornhauser, Samar Issa, Devendra K. Hiwase, Mark Hertzberg, Anthony P. Schwarer, Robin Filshie, Christopher K. Arthur, Yiu Lam Kwan, Judith Trotman, Cecily J. Forsyth, John Taper, David M. Ross, Jennifer Beresford, Constantine Tam, Anthony K. Mills, Andrew P. Grigg, Timothy P. Hughes
Journal: Blood
Blood (2015) 125 (6): 915–923.
https://doi.org/10.1182/blood-2014-07-590315
Published: 2015
Includes: Supplemental data
Journal Articles

Maintaining Imatinib ≥600 Mg Daily in the First 12 Months of Chronic Phase CML Treatment Is Associated with Superior Event-Free Survival at 5 Years.

Michael P Osborn, Susan Branford, PhD, Deborah L White, PhD, John F Seymour, PhD, Ruth Columbus, Kerry Taylor, Christopher Arthur, Anthony Schwarer, Julian Cooney, MD, Michael F Leahy, Philip Rowlings, John Catalano, MD, Mark S Hertzberg, MD, PhD, Robin Filshie, PhD, Anthony K Mills, Keith Fay, Simon Durrant, Henry Januszewicz, David Joske, MD, Craig Underhill, Scott Dunkley, PhD, Andrew Grigg, Timothy P Hughes, MD
Journal: Blood
Blood (2009) 114 (22): 1125.
https://doi.org/10.1182/blood.V114.22.1125.1125
Published: 2009
Journal Articles

Early Dose-Escalation in Chronic Myeloid Leukaemia Patients with Low Plasma Imatinib Levels Leads to Equivalent BCR-ABL Values and Drug Levels at 6 Months to Those with Optimal Drug Levels: First Analysis From the TIDEL II Trial of De-Novo Patients Treated with 600mg Imatinib.

Michael P Osborn, Deborah L White, PhD, Verity A Saunders, Bronwyn Cambareri, Susan Branford, PhD, Andrew Menelaou, Bereha Khodr, PhD, Cassandra Slader, Mark Hertzberg, Anthony Schwarer, David Ma, MD, Christopher Arthur, Cecily J. Forsyth, Samar Issa, Yiu Lam Kwan, John Taper, Andrew Grigg, Timothy P. Hughes, MD
Journal: Blood
Blood (2009) 114 (22): 1131.
https://doi.org/10.1182/blood.V114.22.1131.1131
Published: 2009